• Bristol-Myers Squibb denies defensive strategy firstwordpharma
    March 15, 2019
    In a note to investors published late last week, Wolfe Research analyst Tim Anderson suggested that when probed by sell-side analysts, Bristol-Myers Squibb management has so far “stopped short of saying whether there has been any informal indication of in
PharmaSources Customer Service